[go: up one dir, main page]

SI21170A - Nova uporaba peptidnega razreda spojine za zdravljenje nenevropatske vnetne bolečine - Google Patents

Nova uporaba peptidnega razreda spojine za zdravljenje nenevropatske vnetne bolečine Download PDF

Info

Publication number
SI21170A
SI21170A SI200220008A SI200220008A SI21170A SI 21170 A SI21170 A SI 21170A SI 200220008 A SI200220008 A SI 200220008A SI 200220008 A SI200220008 A SI 200220008A SI 21170 A SI21170 A SI 21170A
Authority
SI
Slovenia
Prior art keywords
lower alkyl
pain
group
aryl
compound according
Prior art date
Application number
SI200220008A
Other languages
English (en)
Slovenian (sl)
Inventor
Norma Selve
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI21170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of SI21170A publication Critical patent/SI21170A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200220008A 2001-03-20 2002-03-19 Nova uporaba peptidnega razreda spojine za zdravljenje nenevropatske vnetne bolečine SI21170A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106891A EP1243262B1 (fr) 2001-03-20 2001-03-20 Nouvelle utilisation d'un composé peptidique pour le traitement de la douleur inflammatoire non-neuropathique
PCT/EP2002/003034 WO2002074784A2 (fr) 2001-03-20 2002-03-19 Nouvelle utilisation d'une classe de composes peptidiques pour le traitement de douleurs inflammatoires non neuropathiques

Publications (1)

Publication Number Publication Date
SI21170A true SI21170A (sl) 2003-10-31

Family

ID=8176844

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200230842T SI1373300T1 (sl) 2001-03-20 2002-03-19 Nova uporaba spojine peptidne vrste za zdravljenje nenevropatske vnetne bolečine
SI200220008A SI21170A (sl) 2001-03-20 2002-03-19 Nova uporaba peptidnega razreda spojine za zdravljenje nenevropatske vnetne bolečine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200230842T SI1373300T1 (sl) 2001-03-20 2002-03-19 Nova uporaba spojine peptidne vrste za zdravljenje nenevropatske vnetne bolečine

Country Status (30)

Country Link
US (3) US6803481B2 (fr)
EP (2) EP1243262B1 (fr)
JP (1) JP4955906B2 (fr)
KR (1) KR100773100B1 (fr)
CN (2) CN100415225C (fr)
AT (2) ATE327744T1 (fr)
AU (1) AU2002257681C1 (fr)
BR (1) BR0205823A (fr)
CA (1) CA2419397C (fr)
CY (3) CY1105533T1 (fr)
CZ (1) CZ20032763A3 (fr)
DE (3) DE60120104T2 (fr)
DK (2) DK1243262T3 (fr)
EA (1) EA007532B1 (fr)
ES (2) ES2262567T3 (fr)
FR (1) FR09C0041I2 (fr)
HU (1) HUP0303600A3 (fr)
IL (2) IL154087A0 (fr)
LU (1) LU91590I2 (fr)
MX (1) MXPA03008467A (fr)
NL (1) NL300399I1 (fr)
NO (1) NO20033629L (fr)
NZ (1) NZ523865A (fr)
PL (1) PL216213B1 (fr)
PT (2) PT1243262E (fr)
SI (2) SI1373300T1 (fr)
SK (1) SK287539B6 (fr)
UA (1) UA82645C2 (fr)
WO (1) WO2002074784A2 (fr)
ZA (1) ZA200300858B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348646T3 (es) * 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (fr) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
CA2562937A1 (fr) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Utilisation de composes peptidiques destinee a la prophylaxie et au traitement de maux de tete chroniques
EP1604654A1 (fr) 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
EP1604655A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (fr) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
WO2006079547A2 (fr) 2005-01-28 2006-08-03 Schwarz Pharma Ag Lacosamide pour traitement d'appoint
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (fr) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
ATE530175T1 (de) * 2006-06-08 2011-11-15 Ucb Pharma Gmbh Therapeutische kombination für schmerzhafte medizinische zustände
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
EP1873527A1 (fr) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (fr) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité
WO2011037833A2 (fr) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Nouveaux dérivés à substitution n-benzylamide d'acide 2-(acylamido)acétique et d'acides 2-(acylamido)propioniques : agents neurologiques puissants
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
EP2468261A1 (fr) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
PL2858496T3 (pl) * 2012-05-10 2023-09-11 Solutex Na Llc Oleje o działaniu przeciwzapalnym zawierające naturalne wyspecjalizowane mediatory prorozdzielcze i ich prekursory

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (fr) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
ES2139183T3 (es) * 1994-01-22 2000-02-01 British Biotech Pharm Inhibidores de las metaloproteinasas.
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
JP3787605B2 (ja) 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) * 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
BR9814951A (pt) 1997-10-31 2000-10-03 Basf Ag Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
EP1137642B1 (fr) 1999-09-03 2007-12-05 Actelion Pharmaceuticals Ltd. Bis-sulfonamides
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
CA2418455A1 (fr) 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Utilisation de derives d'amides d'acide valproique et d'amides d'acide 2-valproenique pour le traitement ou la prevention de la douleur et/ou des cephalees
ES2348646T3 (es) 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
MXPA03008639A (es) 2001-03-27 2005-03-07 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolinas.
CN1520283A (zh) 2001-04-26 2004-08-11 ����˹�ж�-����˹˹������˾ 通过结晶作用控制的压紧性
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
CA2505361A1 (fr) 2002-11-11 2004-05-27 Bayer Healthcare Ag Derives de phenyl- ou heteroarylamino-alcanes comme antagonistes du recepteur ip
ATE384078T1 (de) 2002-11-18 2008-02-15 Bioprospecting Nb Inc Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
DE60311875T2 (de) 2002-12-19 2007-08-30 Pharmacia Corp. Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
EP1589959A2 (fr) 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methodes destinees a traiter les troubles du tractus urinaire inferieur au moyen de modulateurs du canal sodique
WO2004066987A2 (fr) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methodes destinees a traiter les troubles du tractus gastro-intestinal au moyen de modulateurs du canal sodique
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (fr) 2003-12-02 2005-06-08 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la douleur neuropathique centrale
ATE428413T1 (de) 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (fr) 2003-12-05 2005-06-15 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la status epilepticus et etats connexes
EP1579858A1 (fr) 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CA2562937A1 (fr) 2004-04-16 2005-10-27 Schwarz Pharma Ag Utilisation de composes peptidiques destinee a la prophylaxie et au traitement de maux de tete chroniques
EP1604654A1 (fr) 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604655A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
NZ552651A (en) 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (fr) 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (fr) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 pour la thérapie adjuvante de la schizophrenie
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain

Also Published As

Publication number Publication date
NL300399I1 (en) 2009-10-01
NO20033629D0 (no) 2003-08-15
EP1373300B1 (fr) 2009-05-20
ES2262567T3 (es) 2006-12-01
PL362985A1 (en) 2004-11-15
SK287539B6 (sk) 2011-01-04
FR09C0041I1 (fr) 2009-10-30
SK12832003A3 (sk) 2004-02-03
CY2009013I2 (el) 2012-01-25
BR0205823A (pt) 2003-10-21
ZA200300858B (en) 2003-07-09
CN1498103A (zh) 2004-05-19
MXPA03008467A (es) 2003-12-08
US6803481B2 (en) 2004-10-12
CN101332292B (zh) 2012-06-20
CZ20032763A3 (cs) 2004-01-14
HUP0303600A3 (en) 2011-11-28
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
DK1243262T3 (da) 2006-10-02
SI1373300T1 (sl) 2009-10-31
WO2002074784A2 (fr) 2002-09-26
KR20040004369A (ko) 2004-01-13
DE60120104D1 (de) 2006-07-06
JP2004524340A (ja) 2004-08-12
KR100773100B1 (ko) 2007-11-02
CA2419397A1 (fr) 2002-09-26
DK1373300T3 (da) 2009-08-31
HK1058368A1 (en) 2004-05-14
US20050085423A1 (en) 2005-04-21
DE60120104T2 (de) 2006-09-21
FR09C0041I2 (fr) 2010-01-22
AU2002257681B2 (en) 2007-06-07
WO2002074784A3 (fr) 2002-11-21
NO20033629L (no) 2003-08-15
US20070054962A1 (en) 2007-03-08
LU91590I2 (fr) 2009-10-05
IL154087A (en) 2010-05-17
CY1109308T1 (el) 2012-01-25
EA200300932A1 (ru) 2004-04-29
PT1373300E (pt) 2009-07-22
CY1105533T1 (el) 2010-07-28
EP1243262B1 (fr) 2006-05-31
US20030171300A1 (en) 2003-09-11
HUP0303600A2 (hu) 2004-03-01
PT1243262E (pt) 2006-10-31
CA2419397C (fr) 2009-09-15
AU2002257681C1 (en) 2008-02-21
ES2326627T3 (es) 2009-10-16
ATE431833T1 (de) 2009-06-15
EA007532B1 (ru) 2006-10-27
NZ523865A (en) 2004-12-24
AU2002257681A2 (en) 2002-10-03
ATE327744T1 (de) 2006-06-15
IL154087A0 (en) 2003-07-31
DE60232407D1 (de) 2009-07-02
CN100415225C (zh) 2008-09-03
CN101332292A (zh) 2008-12-31
JP4955906B2 (ja) 2012-06-20
US8053476B2 (en) 2011-11-08
DE122009000053I1 (de) 2010-05-27
EP1243262A1 (fr) 2002-09-25
EP1373300A2 (fr) 2004-01-02
CY2009013I1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
SI21170A (sl) Nova uporaba peptidnega razreda spojine za zdravljenje nenevropatske vnetne bolečine
US20090018197A1 (en) Methods for treating status epilepticus and related conditions
CA2565051C (fr) Nouvelle utilisation de composes peptidiques pour traiter la dyskinesie
US20100256241A1 (en) Method for treating atypical facial pain
AU2005226928B2 (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
AU2002257681A1 (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
US20050209163A1 (en) Novel use of peptide compounds for treating central neuropathic pain
KR20070045271A (ko) 골암 통증, 화학요법- 및 뉴클레오시드- 유도 통증의치료를 위한 펩티드 화합물의 용도
HK1049960A (en) Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
HK1058368B (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
KR20070010135A (ko) 통증성 당뇨병성 신경병증의 통증 치료를 위한 펩티드화합물의 신규한 용도
KR20070018067A (ko) 삼차 신경통의 통증을 치료하기 위한 펩티드 화합물의신규한 용도
KR20070010168A (ko) 운동장애 치료를 위한 펩티드 화합물의 신규한 용도

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20101025